Omnicom Health Group’s Post

Unlock the future of healthcare with #PGXtesting from Gold Coast Diagnostics. Our advanced pharmacogenomic testing services are transforming patient care in hospitals and behavioral health facilities. By analyzing individual genetic profiles, we empower healthcare providers to personalize treatment plans, minimizing adverse reactions and maximizing therapeutic efficacy. #PrecisionMedicine #HealthcareInnovation With our comprehensive #PGXtesting solutions, healthcare professionals can confidently select medications aligned with each patient's unique genetic makeup. Say farewell to the uncertainty of trial-and-error prescribing and embrace precision medicine that enhances outcomes and patient satisfaction. #PersonalizedMedicine Join us in revolutionizing healthcare delivery. Partner with Gold Coast Diagnostics and unlock the full potential of personalized medicine through #PGXtesting. #HealthcareTransformation #MedicalAdvancements

Discover the Power of Personalized Health with Vitruvion At Vitruvion, we're dedicated to revolutionizing health and wellness through the power of genomics. Whether you’re a seasoned practitioner or just beginning to explore the potential of personalized health strategies, we invite you to discover how our cutting-edge genomic and biomarker tools can enhance your practice and client outcomes. Why Choose Vitruvion? Advanced Genomic Insights: Harness detailed genetic data to tailor health interventions that truly match your clients' individual needs. Improve Health Outcomes: Utilize our tools to develop personalized strategies that lead to more effective results in wellness and disease prevention. Empower Your Practice: Stand out in your field with the ability to offer scientifically backed, personalized health plans. Interested in learning more? Visit our website or contact us today to explore how Vitruvion can help you lead the way in personalized healthcare. #PersonalizedHealth #Genomics #Vitruvion

Normal ranges in blood tests almost aren't worth the paper they're printed on. All they really give you is a measure of how sick you are based on population averages of a population that is becoming increasingly more dysfunctional from a health perspective. That's why at FDX we use optimal reference ranges of the 130+ biomarkers we can measure. It means we have a super-accurate picture of what's happening when it comes to clients - but also allows us to look at all the interactions between biomarkers to create targeted protocols that work. If you want to optimise your clients' health and grow your clinic, there's only one choice: FunctionalDX. See our website for more https://buff.ly/2G3fcbF

Using real-world data (RWD) and real-world evidence (RWE) to improve the quality of patient care is about asking questions, says Nicholas Robert, MD. Questions about treatment patterns and outcomes in the real world, biomarker testing, and social determinants of health (SDOH) can help evaluate whether patients are receiving appropriate care. #RWD #RWE #SDOH #Biomarkers

Today is #rarediseaseday2024 and in this article Sprout Health Solutions' Beverly Romero discusses how we can overcome challenges in rare disease patient research 👉 https://lnkd.in/eSDDd2FQ

Finding the right patients for a new drug is like finding the perfect puzzle piece - crucial for success, especially in complex cases like Sickle Cell Disease (SCD). Traditional methods often struggle, hampered by both the intricate patient journey and limited data. But what if you could unlock the missing piece? This case study dives into how we helped a client identify the ideal healthcare professionals (HCPs) for their SCD treatment. Through innovative strategies, we achieved remarkable outcomes: 🔺8% rise in identified potential patients. 🔺Recognition of 68% of top-tier hospitals and their HCPs Click here to delve deeper into this success story.👇 https://bit.ly/3vsNodp #insight #sicklecell #raredisease #healthcare

🌟 Overcoming Challenges in Rare Disease Patient Research 🌍 The small populations linked with rare and ultra-rare diseases pose significant challenges for pharma and biotech companies. In the February issue of PME, Sprout Senior Principal Beverly Romero shares five strategies to navigate these complexities in qualitative patient research. 📊 Based on Sprout Health Solutions extensive experience, these strategies include innovative approaches to recruitment and a patient-focused methodology for data collection. 🤝📝 📚 Read more! 👉 https://lnkd.in/eSDDd2FQ #RareDisease #PatientEngagement #PharmaInsights #HealthTech #RareDiseaseAwareness #PatientAdvocacy #HealthcareResearch #ClinicalTrials #PatientVoice #QualitativeResearch #PatientResearch #PatientData #PatientRecruitment

Our Senior Vice President of HCP and Patient Engagement, Catherine Nester, wrote an article for this month’s issue of Exceptional Parent Magazine in which she examines the critical need for enhanced #NewbornScreening capabilities to diagnose #RareDiseases. She discusses the difficult diagnostic odyssey families face and examines encouraging new initiatives that are addressing these challenges.      Read the full article on page 25 of the digital issue: https://bit.ly/3UtGfnt      #InfantHealth #Diagnosis #Biotech 

"We owe it to our patients to get it right." - Lisa McShane Additional insight in her answer was how much patients hang by every test. *This* is why we need to open up patient crowdsourcing of science through patient ownership of their data and empowered engagement with research. Once we accomplish this, real world evidence (RWE) generation will stand to blow the clinical trial/ experimental approach to medical developments out of the water. The clinical trial is just a historical artifact that we are having difficulty shedding, and which does NOT scale in a world of big data and AI. Small scale, top down "experiments" is not how we get at complex systems causality OR understanding, and should much less be considered the gold standard for evidence generation. RWE through empowered patients who own their data has to be looked at as the completely new and the up and coming approach, and RWD needs to stop ✋️ trying to be hammed into clinical trial derived "fit for purpose" little boxes. Let's switch the "fit for purpose" hyperfocus which is myopic and a relic from past frameworks, to patient ownership through web 3 and blockchain as the way to accelerate translation of new technologies and science to patient benefit, as the way to accelerate their use within the clinical encounter. Our antiquated and bloated systems in place will not do this, but I have confidence that patients WILL.

The number of tests is growing so fast that plans cannot keep up with their intended use, applicability, or quality. To add to the difficulties, most tests do not require regulatory approval or oversight, and they have limited ability to validate quality and clinical validity as they quickly enter the market. In Chapter 3 of Transforming the Management of Genetic Testing, we explore how health plans, healthcare providers, labs, and patients all stand to benefit from improving the management of genetic tests and an innovative approach to genetic test management that scientifically validates tests, ensures that the right tests are ordered at the right time, improves reimbursement accuracy, and integrates the results into timely patient care. Read more: https://ow.ly/vT4W50SHAWq #AvalonHCS #GeneticTesting #LaboratoryBenefitsManagement #HealthPlans